Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024

Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6, 2024

Amphastar Pharmaceuticals to Present at the 2024 Wells Fargo Healthcare Conference

AMP 2024 Q2 Earnings Release [CLEAN] 20240805

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7, 2024

Amphastar Announces Additional $50 Million Increase to its Share Buyback Program

Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol

Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care Conference

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2024

Amphastar Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference

Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023

Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2024

Amphastar Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Amphastar Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference

Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2023

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2023

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2023

Amphastar Pharmaceuticals Completes Acquisition of BAQSIMI® from Lilly

Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2023

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2023

Lilly to Divest BAQSIMI to Amphastar

Amphastar Pharmaceuticals Business Update and Hold Conference Call on April 24th, 2023

Amphastar Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mg

Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2023